United States News Todas as matérias

Boeing (NYSE:BA) delivered 171 commercial aircraft in 2Q26, led by 129 737s, bringing its first-half total to 314 units.

Three Chinese firms received U.S. approval to purchase advanced AI chips from Nvidia (NASDAQ:NVDA) and Advanced Micro Devices (NASDAQ:AMD), expanding the licensed customer group.

Meta Platforms (NASDAQ:META) was sued by 26 current and former employees who allege its AI-assisted layoff process disproportionately selected workers with disabilities or protected leave.

Bristow Group (NYSE:VTOL) completed its $105 million acquisition of Berry Aviation from Acorn Capital Management, expanding its government and special-mission aviation operations.

NextNRG (NASDAQ:NXXT) reported preliminary June 2026 revenue of $8.9 million, up 26%, while gross profit increased approximately 44% to $654,000.

Citigroup (NYSE:C) reported Q2 2026 net income of $5.83 billion, or $3.15 per share, as revenue rose 14% to $24.77 billion.

CervoMed (NASDAQ:CRVO) reported new Phase 2b analyses linking neflamapimod benefits to low pTau181 levels and sufficient drug exposure in the 159-patient RewinD-LB trial.

Ranger Energy Services (NYSE:RNGR) announced a new agreement to provide three additional ECHO hybrid workover rigs to Hess Corporation (a subsidiary of Chevron (NYSE:CVX)), marking a continued expansion of its electrified rig fleet.

Hemab Therapeutics (NASDAQ:COAG) shared Phase 2 long-term extension data for its drug candidate sutacimig, which demonstrated sustained prophylactic bleed reduction across 34 patients with Glanzmann thrombasthenia.

HCA Healthcare (NYSE:HCA) expects preliminary second-quarter revenue of $20.230 billion, an 8.7% increase from $18.605 billion in the same period of 2025.

IBM (NYSE:IBM) expects preliminary second-quarter revenue of $17.2 billion, up 1% but below analysts’ $17.86 billion estimate.

America’s Car-Mart (NASDAQ:CRMT) reported fiscal 2026 revenue of $1.28 billion and a net loss of $16.79 per share.

Atrium Therapeutics (NASDAQ:RNA) received FDA clearance for its Investigational New Drug application to begin a 37-participant Phase 1/2 clinical trial.

Xanadu (NASDAQ:XNDU) and Lockheed Martin (NYSE:LMT) announced a strategic collaboration to expand internal quantum programming training.

Summit Therapeutics (NASDAQ:SMMT) sold its investigational Phase III precision antibiotic ridinilazole to Biossil for up to $105 million.

Fastenal (NASDAQ:FAST) reported second-quarter revenue of $2.39 billion and earnings per share of $0.33.

Bank of America (NYSE:BAC) reported second-quarter earnings per share of $1.21 on $31.6 billion in total revenue.

JPMorgan Chase (NYSE:JPM) reported a second-quarter earnings per share of $7.70 on $57.35 billion in total revenue.

Wells Fargo (NYSE:WFC) reported a 17% increase in net income to $6.41 billion for the second quarter.

Spero Therapeutics (NASDAQ:SPRO) licensed SP001 from Innovent Biologics in an agreement valued at approximately US$1.1 billion.

NextCure (NASDAQ:NXTC) agreed to merge with privately held Avere Therapeutics in an all-stock transaction supported by a concurrent $320 million private placement.

Beam Global (NASDAQ:BEEM) reported preliminary Q2 2026 revenue above $8.5 million, up more than 170% sequentially and over 20% annually.

AngioDynamics (NASDAQ:ANGO) reported fiscal fourth-quarter revenue of $86.6 million, up 8%, as Med Tech growth offset a wider $11.4 million GAAP net loss.

Unity Bancorp (NASDAQ:UNTY) reported second-quarter net income of $14.5 million, or $1.42 per diluted share, compared with US$14.3 million and US$1.40 in the previous quarter.